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resumo 
 
 
O crescimento e progressão do cancro da mama é maioritariamente 
dependente da estimulação hormonal, nomeadamente pela hormona ovariana 
estrogénica. Esta hormona liga-se e ativa o recetor de estrogénio a (ERα) que 
culmina na transativação de genes que por sua vez gera uma resposta celular 
ao nível da proliferação e sobrevivência celular. Uma das terapias para 
cancros dependentes de estrogénio é a terapia hormonal. Porém, apesar de 
eficaz, a longo tempo gera mecanismo de resistência endócrina e até 
recorrência. A ativação de vias de sinalização dependentes de fatores de 
crescimento e outras vias de sinalização alteram a estrutura do ERα, a sua 
estabilidade e função. Estes mecanismos são os propostos para explicar a 
resistência endócrina. A estabilidade e atividade do ERαsão processos 
regulados por modificações pós traducionais bem como a degradação da 
proteína mediada pelo proteossoma. A metilação do ERαpela SETD7 parece 
contribuir para a estabilidade e atividade transcricional do recetor. Tal, 
traduzir-se-ia num aumento de sobrevivência celular. Contudo, resultados 
anteriores do laboratório indicam que a SETD7 inibe a proliferação celular de 
células epiteliais mamárias. Assim, este estudo tem como objetivo principal 
estudar a regulação do ERα pela SETD7 e vice-versa, bem como os efeitos 
desta regulação ao nível da proliferação celular mediada por diversos 
estímulos mitogénicos, e com foco nos efeitos dos estrogénios. Para tal, 
realizámos vários estudos utilizando um inibidor da atividade da SETD7, R-
PFI. Neste estudo mostrámos que os níveis de SETD7 diminuem quando as 
células são estimuladas a proliferar. A inibição da atividade da SETD7 pelo 
R-PFI origina um aumento do número de células. Contudo, quando 
combinado com estrogénio, o aumento deixa de ser significativo devido a uma 
paragem no ciclo celular. Na presença de R-PFI, pudemos observar um 
incremento dos níveis proteicos de ERa idênticos aos que se verificam 
quando o proteossoma está inibido, sugerindo um controlo dos níveis 
proteicos de ERa pela SETD7 poderia estar associado ao controlo da 
degradação do ERα. Contudo, este aumento dos níveis de ER não se traduz 
num aumento de atividade do recetor, pelo que a SETD7 parece ser 
dispensável para a atividade do ERα. Os resultados obtidos sugerem um papel 
inibitório da SETD7 sobre o crescimento de células mamárias na ausência de 
estradiol. Por outro lado, os nossos resultados não estão de acordo com 
estudos já publicados, pelo que será necessário aprofundar os estudos para 
esclarecer qual a função da SETD7 na regulação da proliferação mediada pelo 
ERα. 
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Breast cancer growth is dependent on stimulation by the ovarian hormone 
estrogen. Estrogen activates estrogen receptora (ERa) which is a ligand-
activated transcription factor. Estrogen-bound ERa transactivates genes which 
stimulate proliferation and survival. Hormonal therapy is an effective strategy 
to treat hormone-related breast cancer. However, it is associated with 
endocrine resistance and recurrence. Activation of growth factors signaling 
pathways and alterations on ERα protein have been propossed as  resistance 
mechanisms. ERa protein stability and activation of transcription is regulated 
by post transcriptional modifications such as methylation and by proteasome 
degradation. SETD7 is a methyltransferase which targets histones and others 
non-histone proteins important for cellular proliferation, including ERa. 
Methylation of ERa seems to contribute to ERa stability and activity; this 
would lead to an increase in cell survival. However, previous results from our 
lab indicate that SETD7 inhibits mammary epithelial cell proliferation. 
Therefore, in this project, we intent to study the co-regulation between ERa 
and SETD7 as well as the subsequent effects on proliferation in response to 
different mitogenic stimuli, with focus on estrogen. For this purpose, we used 
a SETD7 activity inhibitor known as R-PFI. In this study, we show that SETD7 
levels decrease when cells are stimulated to proliferate. Inhibition of SETD7 
activity by R-PFI leads to an increase in cell number. However, when cells 
were co-treated with R-PFI and estrogen the increase was not significant once 
cells suffer a cell cycle arrest. In the presence of R-PFI, we show an increase 
of ERa protein levels, identical to the levels obtained when ERa degradation 
is impaired by blocking the proteasome, suggesting that SETD7 may control 
ERa protein levels at this level. However, this increase of ERa levels did not 
translate into an increase of ERa activity. Thus, SETD7 can be dispensable 
for ERa activity. Our findings suggest an inhibitory role of SETD7 in breast 
cells growth in the absence of estradiol. But, on the other hand, our results do 
not support studies previously reported in relation to ERa regulation. 
Therefore, further studies are needed to establish SETD7 function in ERα-
induced proliferation.  
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1.1. Introduction 
 
 
Breast cancer is considered the most common type of cancer affecting women and it is the second highest cause 
of female death. Worldwide, it is estimated that 1,4 million women per year are diagnosed with breast cancer, 
while 458.000 die from this disease(1–4). It is considered the main cause of women death in most developed 
countries(4,5). Breast cancer is more common after menopause. Most breast cancer subtypes are ovarian 
hormone-related and  hormone replacement therapy containing estrogen increases the risk of breast cancer (6–
8).  
Estrogen receptor a (ERa) is expressed in approximately 75% of all breast cancers(9). ERa belongs to the 
nuclear receptor superfamily of transcription factors. When activated by its ligand, estradiol, ERa stimulates 
transcription of many target genes, leading to breast tumor cell proliferation. Nowadays, the presence of ERa 
in breast tumours is used to diagnose patients who could benefit from hormonal therapy(10). Because of the 
mechanism of action of ERa, most treatment options involve the blockage of ERa´s estrogen binding site by 
competitive antagonists (such as tamoxifen) or by blocking estrogen synthesis with aromatase inhibitors(11). 
Unfortunately, approximately 50% of ERa-positive breast cancers become resistant to this therapy. Endocrine-
resistance remains a major challenge for effective treatment of ERa+ breast cancer (12). ERa protein 
phosphorylation in specific aminoacids can induce resistance to tamoxifen (13,14). But, further studies in this 
area are needed clearly to understand the mechanisms responsible for the loss of estrogen responsiveness and 
subsequently the acquisition of endocrine resistance. Several post transcriptional modifications (PTM) such as 
methylation, acetylation and phosphorylation, contribute to ERa stability and activity (15,16).  Hence, enzymes 
capable of modifying ERa post transcriptionally can regulate response to therapy. SET domain containg protein 
7 (SETD7), is a lysine methyltransferase initially thought to methylate histone H3 (17). However, SETD7 
methylates many others proteins, most of which regulate the cell cycle both by stimulation or inhibition of its 
progression. Recently, SETD7 was shown to methylate ERa (18). Little is known about the potential of this 
methyltransferase and its role in breast carcinogenesis and disease progression.   
The main goal of this work was to understanding how SETD7 regulates proliferation through EGF effect and 
ERa protein levels and activity in breast cancer cells and non-malignant mammary epithelial cells.  
 
 
 
 
 
 
 
 
 
 
 
1. STATE OF THE ART 
 
 
 
   
2017                                    BEATRIZ MARTINS½IBIMED 
30 
1.2. Classifications of breast cancer subtypes 
 
Breast cancer exhibits distinct phonotypes with different treatment options and different responses associated. 
(19). 
The histopathological classification of breast cancer subtypes takes into consideration the expression or absence 
of three proteins: ERα, progesterone receptor (PR) and Receptor tyrosine-protein kinase erbB-2 (HER2) 
expression (Table 1). This classification related to the breast cancer phenotype have significant differences in 
overall survival and responsiveness to treatment. For example, the expression of ERα and PR, and the absence 
of HER2 protein overexpression is correlated with a better prognosis (20).  
 
ERa positive PR positive HER2 positive Triple Negative Breast Cancer 
PR-/PR+ 
HER2+/HER2- 
ERa+/ERa- 
HER2+/HER2- 
PR-/PR+ 
ERa-/ERa+ 
ERa- 
PR- 
HER2- 
 
Table 1: Histopathological classification of breast cancer. This classification is based on 3 biomarkers classically 
used; ERα: Estrogen Receptor alpha, HER2: PR: progesterone receptor; 
 
1.3. Estrogen signaling and breast cancer 
 
Estrogen is a potent morphogen which stimulates cellular proliferation and differentiation, mainly in breast 
tissue (21). The most relevant estrogen produced by human body is 17ß-estradiol (E2).  E2 effects are mediated 
through two G-protein estrogen receptors (GPER): ERa and ERß, both belonging to the nuclear receptor 
superfamily of transcription factors(22). ERa was first discovered in the late 1950 and ERß in 1998. For this 
reason, ERa is the most extensively studied and currently the only one of the two receptors considered in the 
clinics. 
ERa and ERß have distinct, nonredundant roles in the immune, cardiovascular and sketal systems. On the 
promoter of some genes, ERa and ERß can have opposite effects, suggesting that the overall proliferative 
response to estrogen is the result of a balance between ERa and ERß signaling(23–26). 
ERs contain an amino-terminal region that harbours the ligand independent activating function (AF-1), a central 
DNA binding domain (DBD) and a carboxyl-terminal hormone binding domain (LBD) which contains the 
ligand-dependent activation function (AF-2). The hinge domain determines functional synergy between AF-1 
and AF-2 in response to ERa agonists and antagonists to achieve full transcriptional activity of ER(27). 
Transcriptional activation is mediated by the AFs, the constitutively active AF-1 located at NH2 terminus of 
ERa and the ligand-dependent AF-2 that resides in the COOH-terminal LBD. E2 binds within the hydrophobic 
pocket of the LBD and it is wrapped inside by helix 12. The subsequent conformational change activates AF-2. 
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The central and most conserved domain, DBD, is involved in DNA recognition and concomitant binding 
whereas ligand binding occurs in COOH-terminal on LBD. The NH2-terminal domain is the most variable 
domain in sequence and length between the two ERs (28,29). 
There are four models that explain all ERa actions: 1) classical, direct pathway, 2) tethered, 3) non-genomic 
and 4) ligand independent (Figure 1).   
In the classical direct pathway, E2 binds to ERa in the cytoplasm, and ERa then dimerizes and translocates to 
the nucleus, where interacts with estrogen responsive elements (ERE) on the DNA sequences in target genes. 
The conformational changes in ERa after E2 binding allow the recruitment of coregulators as coactivators or 
corepressors such as  p160 family steroid receptor coactivator 1,2 and 3 (SRC1, SRC2, SCRC3), Rb-interacting 
Zinc-finger protein-1 (RIZ-1), Euchromatic histone-lysine N-methyltransferase 2 (G9a), nuclear receptor-
binding SET domain containing protein-1 (NSD-1), CREB-bindind protein (CBP)/p300, RIP140 and mixed 
lineage leucemia-2 (MLL2) which acts via AF-1 and AF-2 domains(18,30). Some of this coregulators 
complexes contain histone-modifying enzymes proteins as histone acetyltransferase (HAT) which disrupt 
electrostatic bonds on DNA and increase access of transcription factors to the promoter, as well as histone 
methyltransferases (HMT) which alter local chromatin structure and facilitate the recruitment of the 
transcription machinery as components of the RNA polymerase II complex to activate target genes (31,32). 
 In the tethered pathway, ERa does not bind DNA directly, but after ligand activation interacts with other 
transcription factors including stimulating protein 1 (SP-1), activator protein 1 (AP-1) and nuclear factor kappa 
B(NF-kB) which bind to their target DNA sequences (Figure 1). This pathway regulates the expression of  
proteins in cell division, survival and angiogenesis (33). 
The non-genomic pathway, also known as membrane induced steroid signaling (MISS), mediates rapid effects. 
MISS involves the lipidation of ERa located close to membrane. Upon E2 activation, ERa interacts with protein 
kinases (Src and PI3K). In addition, there is a protein known as G-coupled protein aI which can also bind E2. 
Although this is not the ERa we refer to in this work, signaling through E2-activated G-protein can  activate 
protein kinases cascades (Akt, PKA, ERK1/2) and endothelial NO synthase (34–36). 
The ligand independent mechanism, occurs when ERa is activated by AF-1 phosphorylation catalysed by 
activated kinases like protein kinase A (PKA), protein kinase C (PKC) and mitogen activated pathway kinase 
(MAPK), due to the crosstalk with growth factor receptor tyrosine kinase, involving for example insulin growth 
factor receptor (IGFR) and epidermal growth factor receptor (EGFR). ERa activated in this manner can regulate 
transcription of target genes (37–41). 
The current acceptance is that that E2 plays a main role in mammary tumorigenesis. Long term exposure to 
estrogen hormone is associated with an increased breast cancer risk. Furthermore, many studies have reported 
a strong correlation between elevated estrogen levels and breast cancer, involving a hiperactivation of 
ERa(42).Researchers hypothize that E2 acting through ERa stimulates cell proliferation that could originate 
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mutations arising from replication errors during phase S of DNA synthesis. Over a period of E2 exposure, a 
sufficient number of mutations  accumulates and could induce a neoplastic transformation (43,44). 
ERa can interact with cyclin D1 through the PKA-mediated pathway, in response to E2, to promote G1 to S 
transition by activating cyclin D1-regulated cyclin-dependent kinase 4 (CDK-4). Cyclin D1 is also responsible 
for enhancing ERa transcription both in a ligand dependent and independent manner. It was reported that 
mammary epithelial overexpression of cyclin D1 is related to mammary carcinoma (45,46). Moreover, it was 
reported that the ERa gene (ESR1) can be amplified in breast cancers and this is correlated with high ERa 
expression levels and better response to endocrine therapy (47). 
 
 
 
 
Figure 1: Molecular pathways of estrogen signaling. There are four pathways involved on estrogen-mediated 
signaling. Ligand-dependent signaling is subdivided in direct pathway tethered pathway and non-genomic pathway and 
ligand-independent pathway involves a crosstalk with growth factor signaling. ER, estrogen receptor; SM, second 
messengers; TF, transcription factors; NO; nitric oxide; GF, growth factors. Adapted from (37) 
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1.4. Receptors type Tyrosine Kinase in breast cancer 
 
Receptors tyrosine kinase (RTK) are a family of cell surface receptors, which act as receptors for growth factors, 
hormones, cytokines and extracellular signaling pathways. RTK activation by autophosphorylation activates 
signaling pathways regulating cell proliferation, differentiation and apoptosis. The RTKs involve several 
subfamilies such as EGFR, fibroblast growth factor receptors (FGFR), IGFR and HER-2 (48). Activation of 
RTKs triggers a cascade of phosphorylation events involving downstream kinases which leads to the 
phosphorylation of target transcription factors and transcription of specific genes (49). Upon ligand binding, 
RTK are auto-phosphorylated, which results in the activation of Ras/Raf. Then, Raf phosphorylates Erk kinase 
Mek1/2 which in turn phosphorylate Extracellular-signal regulated kinase 1/2 (Erk1/2). These pathway is known 
as MAPK (50). In addition to MAPK, also Phophoinositide 3 kinase/ Protein kinase B (PI3K/Akt) pathway is 
activated by RTK autophosphorylation and it results in the activation of Akt and subsequent activation of 
mammalian target of rapamycin (mTOR). Activation of MAPK leads to translocation of transcription factors to 
the nucleus as c-MYC, influencing cell cycle, while PI3K/AKT result in anti-apoptotic signaling, cell growth 
and proliferation, motility and adhesion. RTK also activates the Janus kinase/signal transducer and activator of 
transcription (JAK/STAT) pathway and the phospholipase Cg (PLCg)  pathway (Figure 2). 
In summary, RTK signaling leads to transcriptional activation of genes involved in angiogenesis, protein 
synthesis, cell proliferation and survival, all biological processes which are altered in cancer cells. In fact, RTKs 
mutations are often associated with tumorigenesis (48). 
 
 
1.4.1. Epidermal Growth Factor family and its receptor 
 
The EGF family of growth factors comprises potent morphogens such as EGF, transforming-growth factor a 
(TGF-A), heparin-binding epidermal growth factor (HB-EGF), amphiregulin (AREG), epiregulin (EPR), 
betacellulin (BTC) and neuregulins (NRGs). 
EGFR is a RTK present in epithelial and stromal cells, that belongs to the ErbB family. When a ligand binds to 
extracellular region of EGFR, the receptor dimerizes, turning on kinase activity following by 
autophosphorylation at multiple tyrosine residues in order to recruit various substrates that activate multiple 
signaling pathways involved on cell proliferation, motility and survival such as PI3K/AKT,  JAK/STAT,  
MAPK kinase and PLCg (51,52). 
EGF, EGFR and EGFR regulators are positively correlated with breast cancer cell proliferation (53). EGFR 
gene is mutated in many epithelial tumours (54). In case of ERa-positive breast cancer, EGFR mediates estrogen 
proliferative effect and promotes invasion of breast cancer epithelial cells (55). Moreover, EGFR 
overexpression in breast cancer is associated with large tumor size and a more aggressive phenotype, and can 
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be involved in resistance to endocrine therapy (55). AREG is transcriptionally regulated by ERa and a key 
mediator of E2-driven epithelial proliferation in mammary gland ductal morphogenesis during puberty (56). 
Several studies suggest that AREG can play a role in human breast cancer initiation and progression and its 
expression is associated with aggressive disease (57). 
HER2 gene and protein overexpression was reported in 30% of invasive breast cancers. HER-2 gene 
amplification in breast cancer potentiates cell proliferation, angiogenesis and tumor invasiveness (58). The 
specific ligand binding of HER2 was not been discovered, however, HER-2 exerts its effects by 
heterodimerization with other Erb receptor family members including EGFR.  
 
1.4.2. Fibroblast Growth Factor (FGF) family and its receptors 
 
FGF is a family of growth factors that mediate cellular responses by activating RTKS designated FGFR1, FGR3, 
FGFR3 and FGFR4. FGFs act in concert with heparin or heparin sulphate proteoglycan (HSP) in order to 
activate their receptors and to induce cellular responses. The binding of FGF2 and HSP to FGFR leads to receptor 
dimerization, activation and autophosphorylation of tyrosine residues and following recruitment of effector 
molecule that lead to stimulation of intracellular signaling pathways such as MAPK and PI3K/Akt (59,60). 
FGFR signaling can play a relevant role in development and progression of breast cancer. Mutations gain of 
function in FGFR were identified in breast cancers (60,61). FGFR amplifications and mutations in breast cancer 
are associated with poor prognosis. Furthermore, it was shown, in MCF7-cells, that FGFR3 can induce 
resistance to tamoxifen mediated by enhanced activation of PLCg signaling (62). 
 
Figure 2: Pathways involved in response to TRK activation. The binding of growth factors to their receptors leads to 
TRK activation by autophosphorylation. Subsequently, it triggers the activation of downstream signaling pathways as 
JAK/SRC, PI3K, Ras-Raf-MEK (MAPK pathway) and PLCg. Activation of these pathways result in expression of genes 
as BCL-X, MYC, CCND1 and CDKN1A important for differentiation, proliferation, survival, oncogenesis and 
angiogenesis. 
Taken from (63)
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1.5. Hippo pathway and its relevance to breast cancer 
 
Hippo pathway is a conserved signaling pathway involved on integration of cytoskeletal changes with 
extracellular environment (64). This signaling pathway negatively regulates cell number by promoting cell death 
and differentiation and inhibiting cell proliferation. The coordination of cellular responses mediated by Hippo 
pathway may contribute to development, tissue homeostasis and tumorogenesis (65–67).  
The Hippo pathway consists in a serine kinase cascade that acts on a transcriptional complex to regulate gene 
expression. The MST1/2 activates another kinase, LATS1/LATS2; which in turn leads to phosphorylation of 
the transcription co-factors Yes-associated protein (YAP) and tafazzin (TAZ), human Sav1 protein (WW45) 
and Mob are regulators that interact with kinases components of Hippo pathway. 
The phosphorylated form of YAP/TAZ interacts with 14-3-3 cytosolic proteins resulting in cytoplasm 
sequestration and an inhibition of target gene transcription. YAP/TAZ may be further phosphorylated by Casein 
kinase 1d/e leading to recruitment of a E3 ubiquitin ligase leading to proteasome-mediated degradation (68,69). 
When upstream kinases MST1/2 and LATS1/2 are inactive, YAP/TAZ remains non-phosphorylated and can be 
translocated into the nucleus to mediate transcriptional activation by interacting with DNA-binding transcription 
factors such as TEA domain family member (TAED), Smad, RNT-related transcription factor (RUNX) to 
regulate genes expression involved in cell proliferation, apoptosis, development and differentiation (67,69). An 
important role of YAP/TAZ-induced proliferation might be transcriptional activation of cell-cycle genes in a 
TEAD- dependent manner. Several studies showed that YAP plays a key role in the regulation of S-phase entry 
and progression as well on G2–M phase, through cyclin D1 transcriptional activation(70). Dysregulation of 
Hippo pathway leads to aberrant activation of YAP that contributes to tumorigenesis in several tissues, 
including breast tissue. Thus the components of Hippo signaling can be considered tumour suppressors once 
they limit cell proliferation (71). 
 
1.5.1. Modulation of Hippo pathway by EGF 
 
Both Hippo and EGFR signaling control cellular growth, and when dysregulated, contribute to abnormal cell 
proliferation. Several growth factors including EGF and Insulin growth factor (IGF) stimulate nuclear 
accumulation of YAP by a downstream effect on PI3K and phosphoinositide dependent kinase 1 (PDK1).  
Ajuba protein can be considered a regulatory mechanism of EGFR and Hippo pathway (72). Mammalian 
contains three Ajuba family proteins Ajuba (Jub), LIM domain containing 1 and Wilms tumor protein 1-
interacting proteins (WTIP)(73). 
In the presence of growth factors, activation of the RAS-MAPK phosphorylates Ajuba protein Jub/WTIP, which 
binds and inhibits the activity of WW45-LATS complex leading to nuclear transactivation of YAP where it can 
exert its transcriptional activity leading to increased cell proliferation (Figure 3).  
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In the absence of growth factors, RTK is not phosphorylated and consequently PI3K remains inactive. PDK1 
forms a complex with Hippo components in order to phosphorylate and retain YAP in cytosol. YAP can’t be 
translocated to nucleus and proliferation mediated by YAP is turned off. 
Growth factors can also activate PI3K and recruit PDK1 to membrane resulting in PDK1-MST1/2-Sav1-
LATS1/2 dissociation which drives YAP translocation and subsequently proliferation-mediated YAP (74). 
Furthermore, it was reported that activation of PI3K by EGFR mediated YAP gene expression and subsequently 
nuclear translocation to interact with TEAD transcription factor in order to upregulate genes involved on 
connective tissue growth factor and AREG genes (75). 
Therefore,  there is a positive feedback mechanism for regulation of these two pathways (72). In breast cancer 
cells, EGFR activation contributes to YAP-mediated cell proliferation and migration (76,77). In MCF-10A non-
malignant mammary cell line, EGF treatment inhibited Hippo pathway (77). 
 
	
	
 
 
Figure 3: Regulation of cellular proliferation mediated by Hippo pathway in the absence or presence of growth 
factors. In the absence of growth factors, RTK is not phosphorylated and PI3K isn’t active. PDK1 forms a complex with 
Hippo components in order to phosphorylate and retain YAP in cytosol. YAP can’t be translocated to nucleus and 
proliferation mediated by YAP is turned off. In the presence of growth factors, RTK active phosphorylate downstream 
proteins involved on PI3K and MAPK; Ajuba proteins, phosphorylated by MAPK, form a complex with Sav and Wts 
hippo proteins. YAP is not phosphorylated by hippo effectors and it is translocated to nucleus where activates expression 
of proliferative genes and inhibits apoptotic gene expression. Taken from (74) 
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1.6. Regulation of Estrogen Receptor a expression and function 
 
To assure proteostatic regulation of ERa, the spatiotemporal abundance of this protein must be strictly 
controlled in the cells. The expression and activity of ERa can be regulated at pre- and post-transcriptional 
levels at three distinct levels: protein expression, activity and degradation.  
Epigenetic mechanisms contribute to transcriptional regulation of ERa expression. The activity of ERa protein 
is regulated through post transcriptional modifications (PTM) including methylation, acetylation, 
phosphorylation, sumoylation and ubiquitination. The E2 binding to ERa triggers PTMs to promote target gene 
transactivation and subsequent ubiquitin-mediated ERa proteolysis. 
 
1.6.1. Control of ERa expression 
 
Epigenetic mechanisms regulate estrogen signaling through and ERa gene expression and protein levels. Those 
epigenetics mechanisms include DNA methylation, histone post translational modifications and RNA silencing 
by non-coding RNAs and contribute to regulate ERa expression (78–80). 
Loss of expression of ERa is explained by DNA hypermethylation. DNA-methylation-mediated promotor of 
ESR1 silencing is associated with tumorigenesis. 
In fact, methylation of ERa promoter by Dnmt3 induce recruitment of methyl-CpG binding protein 2 (MeCP2) 
to complete ERa repression and silencing by further methylation (81). Furthermore, overexpression of HDAC1 
impairs ESR1 expression in MCF-7 cells (82). 
Several evidences show that ERa gene CpG islands are hypermethylated in ERa-negative human breast cancer 
cells and unmethylated on ERa-positive (83). DNMT1 is a methyltransferase responsible for the methyl 
transference group to cytosine bases to CpG islands in ERa promotor, inhibiting ERa transcription (84,85). 
The “switch” in histone modifications resulting in chromatin remodelling can contribute to transcriptional 
silencing or activation of ERa. Specifically, methylation in histones H3 or H4 can contribute to activate or 
repress genes transcription. Transcriptional activated ERa is characterized by the presence of acetyl groups on 
H3 and H4, which promotes an open conformation leading to ERa gene expression. The removal of acetyl 
groups by HDAC the chromatin becomes condensed and ERa is transcriptional inactive. 
RNA silencing consists on mRNA post transcriptional degradation induced by small non-coding RNAs. 
miRNAs are a class of small nucleotides that negatively regulate gene expression by inhibiting translation of 
target RNAs or  inducing mRNA degradation (86,87). miRNAs can influence estrogen-regulated gene 
expression by directly reducing ERa mRNA stability or translation.  Studies in MCF-7 cell line reported that 
transfection with an expression vector for miR-206 reduced both mRNA and proteins level of ERa (88). 
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Nuclear hormonal pathways are also involved in ERa gene expression. Some studies show that progesterone 
and androgens also regulate ERa expression(89,90). E2 induced ERa turnover mediated by ubiquitin ligase 26S 
proteasome is linked to ERa transcription but this subject will be further explored in posterior sections. 
 
1.6.2. Regulation of ERa activity 
 
The existence of ERa PTMs such as phosphorylation, palmitoylation, acetylation, ubiquitination, methylation 
and sumoylation regulate ERa activity after and before its binding to the DNA in a ligand-dependent or 
independent manner (Table 2). 
These PTMs on ERa protein determine the binding of coactivators and corepressors to the receptor, and 
therefore affect its transcriptional activity. PTMs located within DBD and AF-1 can condition non-classical 
signaling of ERa whereas HBD/AF-2 PTM can affect the classical pathway of ERa. Residues in the hinge 
domain, localized between DNA binding domain and hormone binding domain, are also commons targets for 
PTMs that affect ERa activity through alteration of receptor stability or regulation of estrogen-dependent gene 
transcription (91).  
ERa phosphorylation is necessary for receptor dimerization and recruitment of specific transcription factors  
chromatin remodelling enzymes that lead to an enhancement of cell proliferation and survival (92).  Acetylation 
of ERa is associated with DNA binding and negative regulation of ligand-induced transcriptional activity (92).  
Lysine methylation is found in ERa (17,93). Methylation of ERa is associated with receptor stability and 
transcriptional activity. ERa is methylated at K266 by SET and MYND protein family 2 (SMYD2) and at K302 
by SETD7 methyltransferase. SETD7 methylation of ERa is involved on stabilization and enhancing the 
transcriptional activity of ERa (18,94). On the other hand, SMYD2-mediated methylation allows the attenuation 
of the chromatin recruitment of ERα to prevent ERα target gene activation under an estrogen-depleted condition 
(32). Some of methylated residues as K302 may also be modified by acetylation, suggesting a coordinated 
regulatory mechanism to take place at these sites (92). ERa palmitoylation on Cys 447 allows to ERa interact 
with other signaling pathways as MAPK and PI3K (95). ERa sumoylation consists of covalent attachment of 
SUMO to a residue in order to facilitate interaction with other proteins. The main sumoylation residues in ERa 
are K266 and K268, present on hinge region of steroid receptor. The process of ubiquitylation usually targets a 
protein for degradation via proteasome pathway or affect protein-protein interactions and subcellular 
localization (96,97). In fact, ubiquitination of ERa in inactive state allows clearance of misfolded ERa, and 
after ligand binding, it provides a mechanism of promoter clearance to allow new rounds of transcription (98). 
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Table 2: Post translational modifications (PTM) on estrogen receptor a and their biological effect 
 
ERa domain 
 
Residue 
 
TPM/Enzyme 
 
Effect on ERa 
 
References 
 S46/47 Phosphorylation by 
PKC 
Ligand-independent 
activation of ERa 
(14) 
 
 
 
 
 
 
 
 
 
 
 
ACTIVATING 
FUNCTION-1 
Y52 Phosphorylation by Src-
like non-RTK 
ERa stability and 
activity  
(99) 
S102 Phosphorylation by 
Erk1/2  
Ligand-independent 
transcription of ERα 
 
(100) 
S104 Phosphorylation by Erk 
1/2  
Important for ERa 
activity and its 
promote tamoxifen 
resistance 
(101) 
S106 Phosphorylation by 
Erk1/2  
Important for ERa 
activity and promote 
tamoxifen resistance 
(101) 
S118 
 
 
 
 
Phosphorylation by 
CDK-7 or Erk1/2 
 
Phosphorylation by 
GSK3 
Sensivity of the ERa 
to the ligand 
Ligand-independent 
activation 
Stabilization of ERa 
and ligand-dependent 
transcriptional activity 
of ERa 
(92,102) 
 S167 
 
Phosphorylation by 
CDK-7  
 
DNA binding and co-
activators binding 
Ligand-dependent 
activation 
(14,92) 
DNA 
BINDING 
DOMAIN 
S236 Phosphorylation by 
PKA 
ERa dimerization 
and DNA binding 
(92) 
 
 
 
K266 Acetylation by histone 
acetylase p300 
 
DNA-binding and 
ligand-independent 
activation 
(33) 
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HINGE 
DOMAIN 
 
Sumoylation by PIAS1, 
PIAS3, Ubc9 
 
 
Methylation by histone 
methyltransferase 
SMYD2 
 
Stimulation of ligand-
dependent ERa 
activity  
 
Attenuation of 
chromatin 
recruitment of ERα. 
Prevent ERα target 
gene activation under 
an estrogen-depleted 
condition. 
 
(92) 
 
 
 
(32) 
K268 Acetylation by histone 
acetylase p300 
 
 
Sumoylation by PIAS1 
PIAS3 and ubiquitin 
conjugating-enzyme 
DNA-binding and 
ligand-dependent 
activation 
 
Stimulation of 
ligand-dependent 
ERa activity 
(33) 
 
 
 
(92) 
K294 Phosphorylation by 
unknown enzyme 
Ligand-dependent 
ERa transcriptional 
activity 
(14) 
K299 Acetylation by p300 DNA-binding and 
ligand-dependent 
activation 
(92) 
K302 Acetylation by histone 
acetylase p300 
 
Methylation by SETD7  
 
 
 
 
Ubiquitylation by 
BRCA1 
Inhibition of ERa 
activation 
 
Stabilization of ERa 
and efficient 
recruitment of ERa to 
its target genes 
 
Induction of 
proteasome-
(92) 
 
 
(33) 
 
 
 
 
 
(103,104) 
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dependent 
degradation of ERα 
K303 Acetylation by histone 
acetylase p300 
Inhibition of ERa 
activation. 
Attenuation of ERa-
driven transcription  
(33) 
S305 Phosphorylation by 
PKB/Akt or PKA  
Regulation of 
K302/K303 
acetylation 
(92) 
 C447 S-Palmitoylation  Plasma membrane 
localization and non-
genomic ERa 
signaling 
(95,105) 
 
HORMONE 
BINDING 
DOMAIN 
Y537 
 
Phosphorylation by Src 
family  
 
Inhibition ERa 
dimerization, ligand-
dependent activation 
and ER activity 
 
(106) 
 S559 Phosphorylation by 
CK2 
ERa binding to 
coregulators 
Inhibition of ligand-
independent 
activation of ERα 
(14) 
 
 
1.6.3. Regulation of ERa stability 
 
The ubiquitin proteasome pathway (UPP) is considered the major system for protein degradation specially for 
proteins with a short life span. This system can also play a role as directing the subcellular localization of 
proteins (107).  The UPP is important in a wide range of cellular processes such as cell cycle regulation, signal 
transduction, differentiation, embryogenesis and development, apoptosis, and carcinogenesis (108). 
A common feature of the proteasome-mediated protein degradation is the covalent attachment of ubiquitin to 
lysine residues of target proteins followed by the formation of polyubiquitin chains. Those ubiquinated proteins 
are then recognized and degradated by 26S proteasome, a protease complex or by the lysosome (109). 
Protein ubiquitination involves three types of enzymes: E1-ubiquitin activating enzyme (E1), E2 ubiquitin-
conjugating enzymes (E2) and E3 ubiquitin-protein ligases (E3). The first step of this cascade is associated with 
 
 
 
1. STATE OF THE ART 
 
 
 
   
2017                                    BEATRIZ MARTINS½IBIMED 42 
activation of ubiquitin in an ATP-dependent manner (Figure 4). The activated ubiquitin forms a thioester bond 
between the C-terminal glycine residue of ubiquitin and a cysteine residue of E1. Then, ubiquitin is transferred 
from E1 to one enzyme of E2 complex. The ubiquitin can be transferred in two ways: directly from the E2 to 
the target protein or indirectly from E2 to target proteins proceeds through an E3 intermediate. E3 covalently 
ligates ubiquitin to Lys residues on the substrate protein and mediates substrate specificity. This protein-
ubiquitination is repeated by a several times and can lead to the formation of a polyubiquitin chain bind to the 
target protein. Ligation of polyubiquitin can serve as tag to target proteins for promote the assembly of signaling 
complexes or proteasomal degradation. In the 26S proteasome, the ubiquinated protein binds to the 19S 
regulatory component and the substrate is subsequently degraded by 20S core particle. The fragments generated 
are hydrolysed to aminoacids(110). 
 
 
Figure 4:  Enzymes and several reactions of the ubiquitin cascade system. X, Y and Z indicate ubiquitin-binding 
proteins. Pi, inorganic phosphate; PPi inorganic diphosphate; Ub, ubiquitin. Adapted from (111) 
 
 
Ligand induced ERa degradation is important to regulate physiological ERa protein levels (112). The UPP 
allows the rapid clearance of ERa to maintain the balance of ERa in response to hormonal stimulation. 
Degradation of the ERa-E2 complex at each round of transcription a way for the cell to adjust transcription 
activation in response to rapid changes in E2 concentration (113). Therefore, E2 stimulation induces ligand-
mediated ERa degradation by UPP in order to control the intensity and duration of E2-ERa signaling. UPP 
degradation is also responsible for regulate transcriptional activity of ERa. In fact, some studies purposed that 
E2-ERa signalling allows the recruitment of coactivators but also E3-ubiquitin ligases with the aim of its own 
downregulation (114). 
E2 forms a stable complex with ERa. This complex sustain transcription for extended periods of time. In the 
absence of E2, the half time of ERa is approximately 5 days, but in the presence of E2 the life time reduces 
substantially to 3 hours (115). ERa turnover results from the formation of polyubiquitin chains on receptor 
lysines and its subsequent proteasomal degradation through UPP. Hinge region lysines are responsible for 
promote ligand-induce receptor turnover (116).  
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As in the presence of estradiol ERa protein is considered a short life protein, it is possible that receptor can be 
a target of UPP. In fact, some studies show that, in vitro, ER a is degradated in UPP-dependent manner 
following by proteolysis in proteasome  (117). 
Recent evidences show that transactivation and quality control of ERa requires estrogen-dependent receptor 
ubiquitination and degradation and that its turning off ERa-mediated transcription also requires ubiquitination 
and degradation (98,109,118). 
Ubiquitin-dependent degradation of ligand-bound receptor molecules is thought to be critical for promoter 
clearance and additional rounds of transcriptional response to estrogen. This mechanism is necessary for 
sustained and controlled transcription at a given promoter take place (92). 
Many proteins are responsible for maintain ERa stability by inhibiting its degradation via UPP, including ERa 
coactivators as mucin-1 (MUC1) and protein interacting with never in mitosis A (PIN1) (119). MUC1 knock 
out MCF7 cells leads to ERa levels decrease, suggesting that MUC1 confers ERa stability (120). PIN1 
associates with ERa to prevent its interaction with E3 ligase (121). Other proteins involved on ERa stability 
are glycogen synthase 3 (GSK3), Rb and SETD7 (94,122).  
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1.7. Breast cancer therapy and mechanism of endocrine resistance 
 
Hormonal therapy works by decreasing the amount of estrogen in the body or blocking estrogen signaling in 
case of breast cancer (Figure 5). The main types of hormonal therapy that may be used are selective estrogen-
receptor modulators (SERMs), aromatase inhibitors (AI), estrogen-receptor downregulators (ERDs) and 
luteinizing hormone-releasing hormone agents (LHRHs). SERMs block the effect of estrogen in the breast tissue 
(123).  
 
 
Figure 5: Cellular mechanism of aromatase inhibitors and tamoxifen. Aromatase inhibitors and Tamoxifen are 
therapies responsible for decrease in ERa signaling pathway through aromatase inhibition and ERa activity respectively. 
Adapted from (114) 
 
 
It is widely accepted that growth factor receptor pathways interact via cross-talk with ERa and thereby affect 
cell growth and resistance (124). Therefore, it is possible that up-regulation of RTK pathways during tamoxifen 
treatment lead to loss of E2 dependence and tamoxifen resistance. Overactivation of EGFR and consequently 
activation of MAPK can contribute to transcriptional repression of ERa gene, resulting in endocrine resistance. 
(125). Co-activators and co-repressors have important roles in mediating transcriptional activation by ERa. 
Alterations in co-regulators expression may be related with therapy-resistance. Co-repressors are usually 
recruited when an antagonist such as tamoxifen binds to ERa. They form a repressor complex with histone 
deactetylases (HDAC), facilitating chromatin condensation and inhibition of gene transcription. Several data 
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suggest that progressive reductions in co-repressor activity in response to tamoxifen therapy may contribute to 
resistance (102) . 
Overexpression of HER2 gene is present in approximately 25% of breast cancer. HER2 confers a more 
aggressive phenotype. Trastuzumab is a monoclonal antibody using for HER2 positive breast cancer. 
Trastuzumab binds to a extracellular domain of HER2/neu and reduces  signaling downstream as PI3K and 
MAPK cascade (126). Cells treated with trastuzumab suffer a cell cycle arrest during G1 phase of the cell cycle 
through downregulation of Akt activation. Trastuzumab inhibits HER2  cell growth through prevention of 
dimerization, downregulation of HER2R, and induction of antibody cellular  cytotoxicity (127,128). 
Despite successful results in HER2 breast cancer, some patients suffer of tumor recurrence after an adjuvant 
treatment reflecting the existence of mechanisms of resistance to trastuzumab. Inactivation of target receptor 
through truncated HER2 receptors lacking extracellular trastuzumab-binding domain, overexpression of 
alternative RTKS and  alterations on downstream pathways as MAPK and PI3K/Akt are mechanisms involved 
on immune resistance (129). Mutated HER2 isoform promotes the continuous activation of oncogenic signaling 
and avoid trastuzumab’s effects. Overexpression of alternative RTKs is a compensatory mechanism for HER2 
inhibition pathway. In some studies, it was reported that increased signaling from HER family as EGFR, HER3 
or HER4 through EGF, BTC, Heregulin can compensate for the inhibition of HER2 signaling mediated by 
trastuzumab (130,131). Furthermore, overexpression of IGFR reduces trastuzumab effects (132).  
One of the most established mechanism of trastuzumab resistance is the loss of phosphatase and tensin homolog 
(PTEN). PTEN is a tumor suppressor that regulates intracellular levels of phosphoinositide 3 phosphate (PI3P) 
and Akt signaling pathway (133). In fact, patients with PTEN loss in breast cancers have poor responses to 
trastuzumab therapy (134,135). Other active mutations on downstream pathways as RAS mutations in MAPK 
are also related with trastuzumab resistance (136).
 
 
 
1. STATE OF THE ART 
 
 
 
   
2017                                    BEATRIZ MARTINS½IBIMED 46 
 
1.8. SETD7, a lysine methyltransferase 
 
 
SETD7 is a lysine methyltransferase that comprises a Su(var)3-9-enhancer of zeste-trithorax (SET) domain in 
its C terminus. SET proteins can be classified according to the lysine residue that they target on histones H3, 
H4 and H2A. The evolutionarily conserved SET domain occurs in the most protein known to possess histone 
lysine methyltransferase activity. Human SETD7 contains a N-terminal ß-sheet domain as well as the conserved 
SET domain. Two residues presented on C terminus of the protein appear to be essential catalytic activity. The 
cofactor S-Adenosyl methionine (AdoMet) binds also to this domain. AdoMet is the principal methyl donor in 
the methyltransferase reaction (137,138). 
High resolution crystal structure identifies SETD7 as a ternary complex, where peptide substrates and co-factor 
binds on opposite surface of the enzyme. Substrate binds to the active site of enzyme through recognition of 
consensus sequence and AdoMet insert its side chain into a narrow tunnel (139). SETD7 tunnel pass through 
the enzyme and connects the peptide and cofactor binding surfaces. In this tunnel, the alignment of methyl group 
allows the transference from AdoMet to the amine in Lysine (140). Further analysis showed that SETD7 
function as a monomethytransferase (139).   
SETD7  substrates are important for a wide range of biological processes such cell cycle regulation, DNA 
damage response, RNA Polymerase II dependent gene transcription, chromatin modulation, cellular 
differentiation and regulation of developmental pathways(141). Consequently, its acceptable consider its role 
on several physiological and pathological processes, as immune and metabolic pathways and cellular oxidative 
stress (142–146). Recent reports demonstrated that SETD7 is involved on cellular differentiation as well as cell 
cycle, apoptosis and metabolism (146–148). 
SETD7 is specifically known by monomethylated Lysine 4 of Histone 3, a specific tag for epigenetic 
transcriptional activity (149). SETD7 plays a role on maintenance of transcription and euchromatine structure 
at islet-enriched genes (145). 
In relation to tumorogenesis, SETD7 is required for Wnt-driven intestinal tumorogenesis and regeneration. This 
enzyme is a part of a complex containing YAP, a hippo target, and ß-catenin. SETD-7-dependent methylation 
of YAP facilities Wnt-induced nuclear accumulation of ß-catenin. These signaling pathways are frequently 
disrupt on cancer development (150). SETD7 was also reported as a mediator of YAP cytosolic retention, as 
mentioned in the previous sections, this contributes to inhibit YAP-nuclear-mediated transcription (151). Other 
studies showed that depletion of SETD7 enhanced the expression of Wnt/ß-catenin target genes as c-Myc and 
cyclin D1 to promote cancer cells proliferation (152). 
Knock down studies reported that when SETD7 expression decrease, breast cancer cells proliferation, migration 
and invasion increase. These effect is mediated by Gli-1 (153). In case of gastric cancer, data suggest that 
SETD7 have tumor suppressor functions and depletion of SETD7 can be associated to gastric cancer progression 
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(154). In breast cancer, SETD7 was associated with a poor outcome. A recent study published that SETD7 
positively regulates cell number by promoting proliferation and preventing apoptosis in breast cancer cell lines 
through regulation of redox response (155). 
 
1.8.1. SETD7 Histone Targets 
 
It was showed that SETD7 methylates H3K4 in vitro and in vivo (156). H3 methylation at K4 (H3K4me) is 
presented at actively transcribed genes. H3K4me enhances transcriptional activation by preventing chromatin 
condensation. Methylation mediated by SETD7 prevents the association of complex that regulates gene 
expression at the level of chromatin, nucleosome remodeling and deacetylase (NuRD)complex, with H3 tail, 
suggesting that methylation of histone tails can have distinct effects on transcription depending on its location 
and enzymes involved on PTM (157). H3K4me inhibits the H3K9 methylation, which is a repressive genetic 
marker associated with heterochromatin (158). Thus, SETD7 H3K4 methylation is associated with an active 
genetic state. 
H2A and H2B are also SETD7 targets, however little is known about the biological effects of these 
modifications on cell context. H2B is methylated exclusively at K15 whereas H2A appears to anchorage several 
methylation sites (159). H1.4 can also be methylated by SETD7. PARP1-mediated ADP –ribosylation of H3 
was shown to promote SETD7-dependent methylation of linker histone variation H1.4. Methylation of H1.4 
influences directly H1 binding to DNA and, likewise, interfere in chromatin compactation and genetic 
expression of H1 target genes (146). 
 
1.8.2. SETD7 Non-Histone Targets 
 
SETD7 was shown to have a very broad target specificity in vitro, including transcriptional regulators involved 
on cell cycle regulation, proliferation, apoptosis, protein degradation such as TATA-box-binding protein 
associated factor 10 (TAF10), p53, Retinoblastoma(Rb), ERa, Signal transducer and activator of transcription3 
(STAT3). SETD7 was also reported to methylate MeCP2, a nuclear protein that recognizes and binds 
methylated DNA, functioning as a promoter or a repressor, depending on the cell context. Higher expression of 
MeCP2 was found in neoplastic breast tissue, especially in ERa positive breast cancer (156).  
p53 is a tumor suppressor, coordinator of the cellular response to stress signals and transcriptional repressor of 
genes involved in cell proliferation, as c-Myc (160). p53 methylation SETD7 methylates p53 resulting on p53 
stabilization, nuclear export inhibition and transcriptional activation of p53 target genes. That lead to an 
increasing in p53-mediated G2/M arrest and apoptosis. Upon stabilization, p53 activates numerous genes 
involved in cell-cycle arrest, DNA repair, or self-regulation (161,162). In response to DNA damage, sirtuin 1 
(SIRT1) methylation catalysed by SETD7, inhibit SIRT1-p53 association, enhances p53 acetylation and lead to 
subsequently p53 transactivation. That culmines on apoptotic cell death (163).   
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However, recent studies indicate that SETD7 is dispensable for p53-mediated transcription response to DNA 
damage (164). So, further studies are needed to clarify the biological role of SETD7 methylation on p53.  
TAFs are transcription factors, part of TAFII complex, that binds gene promoters and regulate gene transcription 
initiation by RNA Polymerase II. SETD7 has a stimulatory effect over TAF10.SETD7 methylation is necessary 
for increasing TAF10 affinity by RNA Polymerase II recruitment(165). 
Forkhead Box O3 (FOXO3) is an activator of genes involved on cellular regulatory pathways including stress 
resistance and cell cycle arrest. FOXO3 methylation by SETD7 at K271 leads to an increase in its transcriptional 
activity (166). 
Retinoblastoma tumor suppressor protein (pRb) is monomethylated at K873 by SETD7, which is necessary for 
its function on cell cycle arrest, transcriptional repression and differentiation (167). 
E2F1 is a transcription activator important for progression through the G1/S transition on cell cycle, also (168). 
SETD7 methylation destabilizes E2F1 which prevents E2F1 accumulation during DNA damage and the 
activation of pro-apoptotic target genes (169). 
STAT3 is also methylated on K140 by SETD7 in response to IL-6 signaling. This methylation a negative 
regulatory event, because its blockade greatly increases the steady-state amount of activated STAT3 and the 
expression of many STAT3 target genes. STAT3 is a transcription factor activated in response to cytokines and 
growth and, when methylated by SETD7, inhibits it binding to DNA promoters genes(170). 
DNA (cytosine-5) Methyltransferase 1 (DNMT1) is also a SETD7 target protein. Methylated DNMT1 peaks 
occur during S and G2 phases of the cell cycle (171,172). This DNA cytosine-5-methyltransferase 1 is involved 
on the specific DNA methylation at CpG residues, normally involved in transcriptional repression. Methylation 
at K142 promoted by SETD7 decreases DNMT1 levels by facilitating its polyubiquitination and subsequent 
proteasome-mediated degradation, demonstrating that signaling through SETD7 represents a regulatory 
mechanism of DNMT1 enzyme turnover (172). 
ERa is the last and more important non-histone target referred in this monography. In vitro assays found that 
monomethylation of lysine 302 in the ERa hinge region is specifically target by SETD7 (94). Posterior studies 
revealed that SETD7-mediated methylation of K302 can be impaired by the mutation of neighbouring K303 
residue (116). Structural studies show two salt bridge between ERa and SETD7 residues (173). SETD7 knock-
down assays reveals that underexpression of SETD7 decreases the steady state level of ERa protein but not 
mRNA(18). This result suggests that K302 methylation modulates ERa stability. Consistent with these findings, 
posterior studies reported that estrogen-mediated transcription is inhibited when SETD7 expression is impaired, 
suggesting that SETD7 is important for ERa activity (18). 
In summary, SETD7-mediated methylation stabilizes ERa and is necessary for the efficient recruitment of ERa 
to its target genes and their subsequently transactivation. Moreover, SETD7-mediated K302 methylation 
stabilizes ERa by directly competition with ubiquitylation enzymes for the same lysine residue (33).  
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E2 stimulates mammary epithelial cell proliferation in breast cancer (174,175). As result, hormone therapy is a 
common treatment for estrogen-receptor positive breast cancer (47,168,169). However, effectiveness of 
treatment is limited by endocrine resistance. One of the resistance mechanisms to endocrine therapy is the 
decrease or loss of ERa expression and/or activity, as well as loss of estrogen dependence even when ERa is 
still expressed. Multiple molecules have been implicated in endocrine resistance, as ERa itself, coregulators 
and factors that deregulate ERα stability, activity and response to endocrine therapies (116,170,171). ERa 
activity and protein levels are regulated by post translational modifications (PTM) (86). SETD7 
methyltransferase is a protein that methylates ERa, which contributes for ERa stability, by blocking the 
ubiquitination of the same residue, and consequently preventing ERα degradation by the proteasome. As result, 
estrogen-mediated proliferation is enhanced (26,166). SETD7 is also involved in regulation of proliferation once 
several checkpoints of cell cycle are SETD7 targets (172). 
 
The major goal of this study is to understand if SETD7 modulates the response to E2 mediated by ERa in 
mammary epithelial cells and in breast cancer cells, and to establish if this regulation could affect cell 
proliferation. 
 
The specific aims of this thesis are: 
• Understand if SETD7 protein levels are regulated by different mitogens, with focus on the effect of 
 estrogens  
• Analyse if SETD7 affects proliferation mediated by ERa 
• Study if SETD7 influences ERa protein levels 
• Study if SETD7 affects ERa activation by analysing the relative expression of an ERa target protein 
(RIP140) 
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3.1. Cell Culture 
 
3.1.1. Agonists and inhibitors 
 
R-PFI-2 (R-PFI) is a potent highly selective and active inhibitor of SETD7 activity with an IC50 value of 2.0±0.2 
nM. This inhibitor competes with SETD7 substrate by occupying the substrate peptide binding groove of 
SETD7 as well the catalytic-binding domain, and by direct contact with donor methyl group of co-factor S-
adenosylmethionine (SAM). R-PFI only binds to SETD7 after the binding of its cofactor SAM to the protein  
(151). R-PFI was diluted in dimethyl sulfoxide (DMSO). The same volume of DMSO was used as negative 
control for R-PFI condition. R-PFI was a kind gift from Dr. Peter J. Brown, University of Toronto. 
The proteasome inhibitor N-[(Phenylmethoxy)carbonyl]-L-isoleucyl-L-α-glutamyl-tert-butyl ester-N-[(1S)-1-
formyl-3-methylbutyl]-L-alaninamide (PSI) inhibits chymotrypsin-like activity of the proteasome. It was 
dissolved in DMSO and the same volume of DMSO was used as negative control for PSI condition. 
EGF and FGF2 are growth factors that stimulate the growth of cells through their receptors tyrosine kinases. 
Both of growth factors were diluted in dH2O. EGF was used at a concentration of 10ng/mL and FGF2 at 
50ng/mL. 
E2 is a steroid hormone that is soluble in absolute ethanol. E2 was dissolved 1000X concentrated and used at a 
concentration of 10nM. The same volume of absolute ethanol was used as control for E2 treatment. 
 
3.1.2. Cell lines 
 
In this project, HC11, T47D and MC4L2 cell lines were used as experimental model. 
HC11 cells (ATCC CRL_3062, American Type Culture Collection, Massanas, VA, USA) express ERa and 
were derived from murine epithelial mammary cells. HC11 cells were grown in complete growth medium 
containing RPMI 1640 medium (Gibco by life technologies Ca, USA), 1% glutamine, 100 µg/mL gentamicin 
(Gibco), 10% Fetal Bovine Serum (Gibco), 10 ng/mL EGF and 5µg/mL insulin medium (Sigma, Aldrich, St. 
Louis, MO, USA).  
T47D (ATCC HTB-133) cells are human breast cancer cells. This cell line is characterized by its epithelial, 
adherent morphology and the expression of ERa. T47D cells were cultured in RPMI 1640 medium 
supplemented with 10% of FBS and 1% PEST.  
MC4L2 is a murine mammary ductal carcinoma cell line. MC4L2 cells express ERa (176). These cells grown 
in DMEM -F12, 1% glutamine, 5mg/mL insulin and10% of FBS. 
All cell lines were grown in 37ºC and 5% CO2 in T-75 culture flaks. The culture medium was renewed every 2-
3 days and the cells were trypsined once the culture reached about 80% confluence. Trypsinization was 
performed using 2-3 mL trypsin-EDTA (Tryple Express Gibco by Life Technologies) for 2-4 minutes at 37ºC.  
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3.2. Cell Counting 
 
Cells were seeded in a 24 well-plate with a cellular concentration of 5x103 cells/mL. The treatments were given 
when they reached 50% confluence and were renewed 48h later. The cells were counted the following day (day 
3 of treatment). For this purpose, the experimental medium was removed and the cells were washed with 500 
µL/well of sterile Phosphate buffer serum(PBS) (137 mM NaCl, 2.7 mM KCl, 1.8 mM KHPO4 and 10 mM 
Na2HPO4 at pH 7.4). The cells were incubated in 200µL/well of pre-warmed trypsin-EDTA for 2-4 minutes and 
incubated at 37ºC, 5% CO2 until complete detachment from the plate. Then, 10 µL of FBS were added to each 
well to stop trypsin reaction and the cells were counted using a Neubeauer counting chamber under a phase 
contrast microscope. Each treatment was carried out in quadruplicate. All experiments were repeated at least 
twice. 
 
3.3. Preparation of protein extracts 
 
To prepare cell lysates, the growth medium was removed and the cells were washed twice with ice cold PBS. 
The cells were gently scraped off the culture dish and transferred to a 1.5 mL microtube and placed on ice. Then 
they were centrifuge at 14000 rpm for 1 minute. The supernatant was discarded and the pellet was stored at -70 
ºC. To extract the total proteins, the pellets were placed on ice and suspended in 100 µL/1x106cells of RIPA 
lysis buffer (150 mM NaCl, 1% Triton X-100, 5mM EDTA, 1% sodium deoxycholate, 0.1% SDS, 25 mM Tris-
HCl pH 7.6) plus proteinase inhibitor (Roche; dilution:1:50), 1mM of DTT and a phosphatase inhibitor Na2VO4 
(1:1000). The resulting suspension was vortexed and incubated on ice for 10 minutes and then vortexed again 
and placed on ice for others 10 minutes. Afterward, the samples were centrifuged at 14000 rpm for 15 minutes 
at 4ºC and the supernatant was transferred to a new microtube and stored at -70ºC. 
 
 
3.4. Protein quantification 
 
Protein was quantified by a colorimetric BCA assay for protein quantification (BioRad, California, USA). 
Bovine Serum Albumine (BSA) was used as protein standard. The curve comprised concentrations 0.3, 0.6, 
1.25 and 2.5 mg/mL BSA using a stock solution of BSA 10mg/mL (Sigma). Two wells were prepared with 5µL 
each of distilled water (dH2O) to obtain the blank value. The samples were diluted 1:4 in dH2O. Then 25µL of 
Bio-Rad DC TM Protein Assay Reagent A plus Bio-Rad DC TM Protein Assay Reagent S (in a proportion of 
1mL of A: 20 µL of S) were added to each well. Finally, 200 µL Bio-Rad DC TM Protein Assay Reagent B 
were added to each well. The plate was covered with parafilm and incubated for 15 minutes at room temperature. 
After incubating, the absorbance of the plate was read on the spectrophotometer at 750 nm. Standard curve was 
estimated by plotting absorbance as a function of concentration for the standards. Protein concentration of each 
sample was determined by extrapolation of standard curve values using linear regression. 
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3.5. Western Blot 
 
The volume corresponding to 20µg protein was mixed with the same volume of Laemmli buffer 2x (60mM 
Tris-HCl pH 6.8, 2% SDS, 10% glycerol, 0.01% bromophenol blue and 16% β-mercaptoethanol) and the final 
volume of all samples was adjusted with dH2O. During this process, samples were always kept on ice. After a 
short spin, samples were denatured at 100ºC for 5 minutes and then placed on ice. 
The proteins were separated according their molecular size by SDS-PAGE (sodium dodecyl sulphate-
polyacrylamide gel electrophoresis). Stacking and running gels were prepared according to the percentage 
required of acrylamide:bisacrylamide. Ammonium persulfate (APS) and tetramethylenediamine (TEMED) 
were added to start gels polymerization. Protein separation was performed at 200V in running buffer (192 mM 
glycine, 25 mM Tris, 3.5 mM SDS) using a Bio-Rad Mini-Protean Electrophoresis System. Then, the proteins 
were transferred from the gel to the nitrocellulose blotting membrane (GE Healthcare, Life Science) with the 
Trans-Blot Turbo System (Bio-Rad) for 30 minutes at 25 V and 1.0 A using transfer buffer (192 mM glycine, 
25mM Tris, 20% Methanol). After transference, the membrane was stained with Ponceau S solution to check if 
the transference had been correctly performed. Then the membrane was washed with dH2O until the bands 
resulting from Ponceau staining were no more visible, to be posteriorly blocked in a blocking solution [5% dry-
milk in Tween-TBS (20mM Tris, 150 mM NaCl, pH 7.6 and 0.05% Tween-20)] for 1 hour. Then, the membrane 
was incubated with the primary antibodies anti-SETD7 (ab14820 abcam; dilution 1:1500), anti-ERa (sc-542, 
Santa Cruz Biotechnology; dilution 1:300)) anti-RIP140 (Santa Cruz Biotechnology; dilution 1:300), anti-
Erk1/2 (Gentex,BD Transduction; dilution 1:1000) and anti-aTubulin(NB600-506, Nouvs Biologicals, CO, 
USA; dilution 1:5000) in Tween-TBS overnight. After incubation with primary antibodies, the membrane was 
washed three times with Tween-TBS for 10 minutes each and incubated with secondary antibodies anti-mouse 
IgG (Sigma, dilution 1:10.000) or anti-rabbit IgG (Sigma, dilution 1:10.000) also diluted in Tween-TBS for 1 
hour at room temperature in agitation.  
To assure that equal amounts of protein were loaded into the wells and validate all variations in target protein, 
we used a housekeeping protein reference, a-tubulin or total Erk1/2. 
After secondary antibody incubation, the membrane was washed twice with Tween-TBS for 10 minutes and 
once with TBS (20mM Tris, 150 mM NaCl, pH 7.6) for another 10 minutes. Detection was performed using a 
chemiluminescent detection assay WesternBright ECL kit (Advansta). Finally, the immunodetection was 
performed using ChemiDoc Image System software (Life Science, Bio-Rad) and the relative intensity of bands 
was determined using ImageLab (Bio-Rad software). 
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3.6. BrdU ELISA 
 
Bromodeoxyuridine enzyme-linked immunosorbent assay (BrdU ELISA) is a colorimetric immunoassay that 
allow us to quantify cell proliferation, based on the measurement of BrdU incorporation during DNA synthesis 
in S phase of cell cycle. For this assay, the colorimetric kit Cell Proliferation ELISA, BrdU (kit of Roche) was 
used. The cells were plated in a 96-well plate in a final concentration of 2x104 cells/mL. When the cells reached 
a 60-70% confluence the treatments were given to cells. Each treatment was carried out in quadruplicates. After 
48 hours, the treatments were renewed and the cells were incubated with 10µM BrdU (Roche, Mannheim, 
Germany) and incubated overnight at 37ºC, 5% CO2. Then 100 µL of FixDenat solution were added to each 
well and the plate was incubated for 30 minutes at room temperature. After removal of FixDenat the cells were 
incubated with 70µL per well of anti-BrdU-POC working solution in a dilution of 1:1000 for 1 hour at room 
temperature. Then, the plate was rinsed three times for 5 minutes each with 200µL of PBS and 70µL of substrate 
solution were added to each well. The cells were incubated at room temperature until colour development was 
sufficient for a colorimetric detection from 5 to 20 minutes. The absorbance was read at 370 nm and 492 nm 
(reference wavelength). 
 
 
3.7. Indirect Immunofluorescence assay 
 
5x103 cells/mL were seeded in a 24-well plate and grown on sterile glass microscope coverslides until they 
reached 70% confluence. Then, the treatments were given to each well and the cells were incubated with these 
treatments for additional 24 hours. Following incubation, cells were washed twice with sterile PBS and fixed 
with 4% buffered formalin for 10 minutes at room temperature. After two washes with PBS, cells were stored 
at 4ºC with 1mL of PBS per well. After storage, the cells were washed twice in PBS for 3 minutes and 
permeabilized with 0,5% Triton X-100 in PBS (250µL/well) for 10 minutes. After washed three times with PBS 
for 3 minutes, the cells were incubated with 250 µL blocking solution (0,01% Tween and 15% FBS in PBS) for 
60 minutes. Following blocking, cells were incubated overnight at room temperature with 250µL/well of the 
primary antibody anti-Ki-67, (abcam; dilution 1:1000) in PBS overnight. The next day, cells were rinsed three 
times in 1 mL of PBS/well for 3 minutes and incubated for 1 hour with the secondary antibody anti-mouse 
(Sigma; dilution 1:400) in blocking solution+DAPI (Sigma-Aldrich, Sto Louis, MO, USA; dilution 0,1µg/mL) 
in PBS and 6 drops of Caspase Kit (ThermoFischer).  
Then, cells were washed with 1mL of PBS/well and mounted in Prolong Gold system (Life Technologies, CA, 
USA). The slides were allowed to dry 24h at room temperature, in the dark and posteriorly analysed under an 
inverted microscope (Nikon, Eclipse Ti-U). 
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3.8. Fluorescence-Activated Cell Sorting Assay 
 
For this assay, the cells were plated on a 3cm diameter plate in a concentration of 2x105 cells/ mL. One plate 
was used as negative control with unstained cells and another plate was considered the initial time point, with 
cells not arrested. After the cells reached a confluence of 70-80%, their cell cycle was arrested with serum-free 
medium for 24 hours. Following 24h arrest, the cells were incubated for 12h and 24h with 10ng/mL EGF. Then, 
the growth medium was collected in a conical tube and the cells were rinsed with PBS before the addition of 
1mL pre-warmed Trypsin-EDTA for 2 minutes at 37ºC. After the complete detachment, the cells were placed 
on the conical tube with 1mL of RPMI supplemented with 10% of FBS to stop trypsin reaction. The plate was 
also washed with 1mL of 10% FBS medium and both fractions were pooled. Subsequently, the conical tube 
with cells was centrifuged at 2500 rpm for 10 minutes and the supernatant was carefully removed. After wash 
the pellet in 1mL of PBS, the tube was centrifuged again at the same conditions and all the volume of supernatant 
was removed. After that, the pellet was gently resuspended in 300µL of ice cold PBS to obtain a single cell 
suspension. Then, the suspension was vortexed softly while 700µL of ice cold absolute ethanol were added and 
the cells were stored at 4ºC overnight. On the next day, the cells were spinned at 2500 rpm for 10 minutes and 
washed in 200µL of staining buffer (0,5% Triton in PBS). Then cells were ressuspended in 1mL of staining 
buffer. Cells were staining with 20µL of propidium iodide (20µg/mL) and incubated for 30 minutes at room 
temperature. Once stained, the cells were analysed in a flow cytometer under 400 events per second. 
 
3.9. Statistical Analysis 
 
All data was analysed by GraphPad software. Differences between control and treatments was analysed using 
one-way ANOVA and Tukey post-test or t-tests in the case of comparison between control with only one 
treatment. Differences between two groups were considered significant if p value < 0,05.
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Previous work carried out into the lab showed that EGF treatment reduces SETD7 mRNA and protein levels in 
HC11 non-tumorigenic mammary epithelial cell line (177). This effect correlated with increased cell number. 
Therefore, we concluded that methylation of specific proteins by SETD7 could be one explanation for the 
reduction of cell population growth in cells without EGF as compared to those grown with EGF. Consequently, 
in cells stimulated with EGF, SETD7 reduction would correlate with lower methylation of target proteins and 
result in increased cell number (Figure 6). Since in this work we aim to study if SETD7 can influence cell 
growth through targeting ERα signaling pathway, and growth factors can influence ERα protein levels and 
activation degree, we first studied if EGF influenced ERα protein levels (178,179). 
 
 
Figure 6: Regulation of EGF mediated by SETD7 in cell number 
 
 
 
4.1. EGF regulation of ERa and SETD7 protein levels  
 
 
It was previously reported that SETD7 methylates and contributes to increase ERa protein stability and, 
consequently, this  induces of cell proliferation (17,18). With the intent of understanding if there is a correlation 
between ERa and SETD7 protein levels in response to EGF treatment, HC11 cells were stimulated with EGF 
for 24h and the levels of ERa were compared with the untreated control, as well as our previous blots of SETD7 
(Figure 7). 
As can be seen, ERa expression in HC11 cell line increased when the cells were stimulated to proliferate with 
EGF while SETD7 protein levels decreased. Therefore, the results show an inverse correlation between SETD7 
and ERa. Notably, others have shown that EGF reduces ERa protein levels, these differences may be related 
to differences on experimental conditions such as EGF concentration (authors used 0,4ng/mL of EGF) or 
incubation times, which is not agree with our results (178). 
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Figure 7: EGF effect on ERaand SETD7 protein levels. A. ERa protein levels in HC11 cells after 24h of incubation 
with and without EGF. 20 µg total protein was separated using a 7,5% SDS-Page. ERa protein levels analysed by WB 
B. Relative intensity after +EGF were normalizes to intensity in -EGF 
C.HC11 cells were depleted of EGF for the indicated time intervals. Afterwards, SETD7 protein levels were analysed by 
Western Blot SETD7 protein levels in HC11. Figure obtained from previous work done in the lab. D. SETD7protein levels 
in HC11 cells after +EGF were normalized to intensity in –EGF. 
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4.2. Regulation of SETD7 protein levels by proliferative signals in breast cancer 
 
In this part of the study, we aimed to analyse if other mitogenic signals besides EGF can influence SETD7 
protein levels in breast cancer cells. We focused on E2, which induces proliferation by direct activation of cell 
cycle genes as cyclin D1, and FGF2 which stimulates proliferation indirectly through the activation of MAPK 
pathway (180,181). 
T47D cells were incubated with 10nM 17ß-estradiol (+E2) or the same volume of ethanol (-E2) for 4h,7h, 16h 
and 24h. SETD7 proteins level decreased at 4h and 7h incubation with E2 and again at 24h (Figure 8). These 
findings suggest that when cells were stimulated to proliferate with E2, SETD7 proteins level decrease in an 
early-event. MC4L2 cell line was incubated with or without FGF2 at a final concentration of 50ng/mL, for 24h. 
FGF2 reduced SETD7 protein levels (Figure 9).  
Therefore, we conclude that two factors that promote proliferation through different mechanisms seem to have 
similar effects on SETD7 protein levels in breast cancer cells at 24h. However, more studies are needed to 
establish if this is sufficient and necessary to promote proliferation induced by either E2 or FGF2. 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8:Effect of estradiol on SETD7 expression A. T47D cells were incubated with 10 nM of estradiol(+E2) or 
ethanol(-E2) for 2h, 4h, 7h 16h and 24h. Twenty µg of total protein was separated using a 10% SDS-PAGE and SETD7 
and housekeeping tubulin protein levels analysed by WB B. Relative values of SETD7 band intensity of +E2/-E2 is in the 
graph when cells were incubated with 10nM E2 and the same volume of ethanol in different time points. 
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Figure 9: Regulation of SETD7 protein expression by growth factor A. MC4L2 cells were incubated with or without 
FGF2 at a concentration of 10ng/mL for 24h. Twentyµg total protein was separated using a 10% SDS-Page SETD7 protein 
levels analysed by WB B. Relative values of SETD7 band intensity of +FGF2 were normalized to intensity in –FGF2 
 
 
 
4.3. SETD7 inhibition by R-PFI resulted in to an increase of cell number 
 
As previously reported, SETD7 protein level is negatively regulated by EGF and FGF2. These growth factors, 
are also needed for the proliferation and survival of cells. This fact suggests that SETD7 may influence cancer 
cell proliferation and, consequently, cell number. To evaluate how this methyltransferase influences cell 
proliferation, a cell counting assay was performed. 
T47D, HC11 and MC4L2 cells were grown in growth factor-free medium and, subsequently, treated with 
different concentrations of SETD7 inhibitor R-PFI (1nM, 8nM or 10nM) or the same volume of DMSO. 
Following SETD7 inhibition, cell number increased in all cell lines (Figure 10). However, each cell lines need 
different concentrations of R-PFI to achieve highest cell number. In T47D and MC4-L2, the maximal cellular 
number was obtained with a concentration of 1nM of R-PFI (Figure 10) and in HC11 this effect was obtained 
with 8nM of R-PFI (Figure 10). These results suggest that SETD7 is necessary to maintain a low proliferative 
state in all three cell lines once SETD7 inhibition increases cell number. 
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Figure 10:Effect of SETD7 inhibition on cell number in T47D, HC11 and .MC4L2. Cells were treated with R-PFI 
1nM, 8nM and 10 nM for 3 days. Then cells were counted in a Neubauer chamber. The graph bars show the mean ±   SD 
from each condition carried out in quadruplicates. Representative of at least 2 experiments. (*) indicates statically 
significant differences between treatment and control (p<0.05). 
 
 
We were also interested to know if the effect observed after SETD7 inhibition was the same in the presence of 
EGF which itself induces a higher population growth rate of the cells. Cell counting assays were performed in 
non-cancer HC11 and cancer T47D cell line, with a concentration of R-PFI of 8nM for HC11 and 1nM for 
T47D. There was an increase in cell number in cells treated with R-PFI in comparison to control condition 
(Figure 11). These results suggest that in a high proliferative state, SETD7 inhibition contributes to the increase 
in cell number. However, the fold of cellular number was lower than in cells grown in the absence of EGF 
suggesting that SETD7 effect can be dependent of EGF (Figure 12). 
In summary, in the presence or absence of EGF, SETD7 methyltransferase activity inhibition lead to an 
expansion in cell population. Thus, we conclude that SETD7 activity inhibits cell population growth which is 
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not corroborated by literature. Several studies report that SETD7 overexpression can promote cell proliferation 
in hepatocellular carcinoma cell line, which do not support  our findings (182). 
 
 
 
 
Figure 11:Effect of SETD7 inhibition in proliferating-stimulated cells. Effect of R-PFI 8nM on cell number in T47D 
and HERE respectively. After 3 days of treatment, cells were counted in Neubauer chamber. Mean ±   SD from each 
condition was carried out in quadruplicates. Representative of at least 2 experiments. (*) indicates statically significant 
differences between treatment and control (p<0.05) 
 
 
 
 
Figure 12: Fold of cellular increase in presence or absence of EGF. Fold was calculated as the median value of cells 
obtained for PFI 1nM in T47D and 8nM in HC11 in relation to the mean value of control in both cell types. 
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The combined effect of R-PFI and E2 in cell number 
 
T47D and HC11 cell lines express ERa which means these cells respond to estrogens and proliferate 
(22,183,184). In addition, others have shown that SETD7 in necessary to enhance ERa signaling(18). So, it 
would be expected that SETD7 inhibition would reduce ERa stimulation of proliferation. Thus, we studied what 
would happen to cell population growth if T47D and HC11 cells were co-treated with R-PFI and E2. In both cell 
lines, cell number increased in response to E2, which was considered a positive control. The same situation was 
verified when cells were incubated only with R-PFI. But, when cells were incubated with both R-PFI and 10nM 
E2, there was no cumulative effect on cell number. In T47D cells the combined effect lead to similar levels as 
induced by E2 alone (Figure 13A). This suggests that SETD7 inhibition did not reduce ERα signaling, but the 
stimulatory effect of R-PFI alone was lost. In HC11 cell line, the combined effect translated into no significant 
differences in relation to the control condition (Figure 13B), that is both E2 and R-PFI effects were lost. In this 
case, it appears that SETD7 inhibition did reduce ERα signaling. Therefore, SETD7 inhibition alone seems to 
drive cell number population growth to higher levels than E2 alone. However, contrary to what we observed in 
cells stimulated with the growth factor EGF, there is no additive effect when R-PFI is combined with E2. 
Moreover, in breast cancer cells ERα signaling is maintained even if SETD7 is inhibited, but this is not observed 
in non-malignant cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: T47D and HC11 cell counting in EGF growth medium. Combined effect of R-PFI and E2 on cell number in 
T47D and HC11 cell line respectively. After 3 days of treatment, cells were counted in Neubauer chamber. Mean ±   SD 
from each condition was carried out in quadruplicates. Representative of at least 2 experiments. (*) indicates statically 
significant differences between treatment and control (p<0.05). 
T47D HC11 
Co
nt
ro
l
E2
 10
 nM
PIF
 1n
M
PIF
+E
2
0
2
4
6
T47D  cells
N
um
be
r o
f c
el
ls
 (x
10
4 )
PIF
E2
EGF
- -
- +
+ + + +
+
+
-
1nM
*
*
*
Co
nt
ro
l
E2
 10
nM
PI
F 8
nM
PI
F 8
nM
+E
2 1
0 n
M
0
20
40
60
80
100
HC11  cells
N
um
be
r 
of
 c
el
ls
 (x
10
4 )
PIF
E2
EGF
-
-
-
-
-
- - -
+ +
8nM8nM
*
*
1nM R-PFI    -              -              +                 + 
 
10nM E2        -                  +               -                  +     
8nM R-PFI        -    -              +                + 
 
10nM              -                 +                -                +     
 
 
 
4. RESULTS 
 
 
   
2017                                    BEATRIZ MARTINS½IBIMED  70 
4.4. SETD7 regulates cell proliferation 
 
In order to explore why the combined effect of SETD7 inhibition with R-PFI and the mitogenic stimulus with 
E2 caused a decrease in HC11 cell number, in comparison to both stimuli alone we analysed if the combined 
treatment caused cell apoptosis and/or cell cycle arrest. 
As a first approach, we intended to study R-PFI, EGF and E2 effects on the cell cycle phases using Fluorescent 
activated cell sorting (FACS). For this purpose, we first carried out a set-up experiment to define the best time 
point to study the cell cycle. We began by incubating HC11 cells with EGF for 12 and 24 h (Supplementary 
information). However, we had problems with the 24h treatment groups. Nevertheless, we were able to observe 
an approximately 20% increase in cells in S phase already after 12h treatment. Unfortunately, the FACS machine 
broke and we could not complete our planed experiments. Therefore, the effect in cell proliferation was analysed 
with a BrdU colorimetric assay in HC11 cell line. As expected, E2 and R-PFI alone stimulated proliferation 
while the combined treatment did not stimulate proliferation (Figure 14). Therefore, we can conclude that 
SETD7 inhibits cell proliferation, possibly being responsible for maintaining a low cell population growth rate. 
Moreover, activation of proliferation by ERα needs functional SETD7, because SETD7 inhibition reduced 
proliferation induced by E2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Effect of E2 and R-PFI on HC11 cellular proliferation. Analysis of BrdU incorporation after 3 days of 
treatments with 10nM E2, 8nM R-PFI or the same volumes of DMSO and Ethanol for control. Mean ±   SD from each 
condition was carried out in quadruplicates. (*) indicates statically significant differences between treatment and control 
(p<0.05) 
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With the aim to confirm the BrdU results and analyse if SETD7 inhibition could have an effect on apoptosis, an 
indirect immunofluorescence assay was performed in HC11 cells, using two distinct markers: the marker for 
cell proliferation Ki-67, and the marker for apoptosis, active caspase-3. The antigen Ki-67 is a nuclear protein 
expressed in proliferating cells, present during cell cycle but absent in non-proliferative cells. These makes Ki-
67 a good marker to compare, by immunoassays, proliferative state within a cell population (185–187). Capase-
3 is frequently activated when the cell enters the programmed cell death pathway, catalysing the cleavage of 
several proteins. Because of that, caspase-3 is considered a specific hallmark of apoptosis (121–123). A positive 
control for apoptosis was obtained by starving HC11 cells in growth medium without serum and glutamine 
(Figure 15). 10nM E2 induced an increase in proliferation, once the Ki-67 signal is higher than control condition 
and the apoptosis decreased. But, after combined 8nM R-PFI and10 nM E2, we can observe a decrease on Ki-
67 signal, and consequently in proliferation, in relation to E2 treatment alone.  
In conclusion, HC11 cells response to E2 with an increase in cell proliferation. However, when ERα is stimulated 
and SETD7 is inhibited the proliferative signal activated by E2 is lost. This explain the results obtained by 
cellular counting when HC11 are treated with both E2 and R-PFI (Figure 13). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: Effect of R-PFI and E2 on cell cycle and aoptosis in HC11. Analysis of Ki-67 antigen marker (red) and 
Caspase-3-mediated apoptosis (green) by indirect immunofluorescence. In blue are cells nuclei stained with DAPI. HC11 
were treated with 8nM R-PFI (or the same volume of DMSO), 10nM E2 (or the same volume of ethanol) for 24hours. 
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4.5. SETD7 regulates ERa protein levels 
 
With the aim to study how SETD7 regulates ERa protein levels in T47D breast cancer cell line, cells were co-
treated with or without R-PFI at a final concentration of 1nM for 24h and 48h. 10nM proteasome inhibitor PSI 
was used as control, to compare how ERa protein levels increased when proteasome is inhibited. When SETD7 
activity was inhibited by R-PFI, ERa protein increased approximately 3-fold and 7-fold higher in relation to the 
control, at 24 hours and 48 hours respectively (Figure 16A and 16B). The same was observed when cells were 
incubated with the proteasome inhibitor because using PSI, proteins tend to accumulate in cell (Figure 16). This 
is in agreement with the knowledge that the proteasome degrades ERa bound to E2 once it has completed 
activation of transcription (188). 
In summary, SETD7 inhibition results in an accumulation of ERa overtime, a similar effect as observed with 
the PSI. Therefore, we propose that SETD7 may induce ERa protein degradation, suggesting that SETD7 might 
inhibit E2-induced proliferation through increased ERa protein turn-over. Alternatively, this may be related to 
inhibition of ERa gene transcription. However, combined SETD7 inhibition -which increases ERa- with E2 
treatment reduce proliferation, this may be related to loss of ERa transcriptional activity and/or reduced 
H3K4me induced in specific genes by SETD7 inhibition. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: Effect of SETD7 inhibition and proteasome inhibition in T47D after 24 and 48 hours A. Cells were co-
treated with R-PFI at 1nM and PSI 10 nM or with the same volume of DMSO in case of control. Twentyµg total protein 
was separated using a 7,5% SDS-Page. Afterwards, ERa protein levels were analysed by WB. B. Relative quantification 
of the intensity of the bands in the blot in relation to 24h and 48h. 
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4.6. ERa protein activity is influenced by SETD7 
 
With the aim to study if SETD7 regulates ERa activity, we analysed the protein levels of an ERa target gene 
by Western blot. We chose nuclear receptor co-repressor nuclear repressor interacting protein 1 (RIP140), a 
transcriptional downstream target gene of ERa(124–126). We incubated HC11 cells in the presence or absence 
of SETD7 inhibitor R-PFI, proteasome inhibitor PSI and E2. HC11 cells were incubated with those treatments 
for 24h. As expected, when HC11 cells were treated with E2, RIP140 protein levels increased (Figure 17). When 
SETD7 was inhibited by R-PFI, RIP140 levels remained similar to the control possibly because of the absence 
of E2 (Figure 17). The co-treatment of cells with both R-PFI and E2, resulted in RIP140 levels similar to E2 alone 
which suggests that SETD7 inhibition does not affect ERa transcriptional activity. When we combined PSI and 
E2, the levels of RIP140 decreased in relation to E2. this was expected because transcriptional activity of ERa is 
dependent on its own degradation in a ligand-dependent manner. 
In summary, while SETD7 inhibition blocks E2/ERα-induced proliferation, this may be related to reduced ERα 
protein levels but not to its activity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: Effect of SETD7 and proteasome inhibition on ERa activity through RIP140 protein levels. A. Cells were 
co-treated with R-PFI at 8nM, PSI 10 nM and E2 or with the same volume of DMSO or Ethanol in case of control. Twenty 
µg total protein was separated using a 12% SDS-Page. Afterwards, RIP140 protein levels and housekeeping T-Erk were 
analysed by WB. B. Relative quantification of the intensity of RIP140/P-EKR protein level in relation to control condition.
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Approximately, 70% of breast cancers express ERa and they initially depend on estrogen signaling for growth. 
Anti-estrogen therapy, as tamoxifen, is the standard treatment for ERa-positive breast cancers. However, its 
efficacy is limited by initial or acquired resistance to endocrine therapy (189,190). The key pathways involved 
in endocrine resistance are: 1) upregulation of growth factors pathways that promote ligand-independent ERa 
activation, 2) loss of ERa expression and 3) the mutant ERathat are constitutively active in the absence of 
estrogen (191–193).Thus, it is important to understand how ERa is regulated in order to achieve a better 
treatment. 
ERa is subject of several post translational modifications, where SETD7 appears to methylate, stabilize ERa 
protein and enhance its transcriptional activity. For this reason, we decided to study SETD7 expression and 
function in breast cancer cells, and understand the biological association between SETD7 with ERa in the 
regulation of cell proliferation.  
Our findings suggest that SETD7 methyltransferase protein levels are down-regulated by proliferative signals 
in cancer, including E2, and the growth factors EGF and FGF2 (194–196). Furthermore, a previous study done 
in our lab showed that SETD7 protein level is inhibited by MAPK activation by EGF. E2, EGF and FGF2 reduced 
SETD7 protein levels, suggesting that SETD7 protein levels must be lowered to allow cell proliferation. Our 
results are supported by literature where one study reported that SETD7 is preferentially expressed in 
differentiated and non-proliferative cells  (147). 
Next, we were interested in understanding the impact of SETD7 inhibition on cell number. Our results show 
that the cellular number increased when SETD7 was inhibited by R-PFI in T47D, HC11 and MC4L2. In breast 
cancer cells 1nM lead to a great cell number and in HC11 cells the maximal number was obtained at 8nM R-
PFI.  We also verified an increase in cell number when cells were co-stimulated with EGF and R-PFI. This 
result can be explained through Hippo pathway regulation by EGF (Figure 18), which negatively regulates 
proliferation(64). When cells are stimulated with EGF, EGF activates downstream pathways as MAPK that 
recruit AJUBA proteins leading to YAP translocation to the nucleus where it functions as transcriptional 
coactivator of proliferation genes by interacting with transcription factors and cyclin D1(197). Previously, we 
showed that MAPK inhibition  decreased SETD7 levels (177), and others have shown that SETD7 methylates 
YAP and promotes its sequestering in the cytoplasm (198). Thus, SETD7 inhibition could impair cytosolic 
retention of YAP, leading to proliferation and concomitant increase of cell number (Figure 18). 
In the absence of EGF and presence of R-PFI, the fold of cell increase observed in the stimulation of cell 
population growth was higher than in cells already stimulated with EGF. This is probably because the 
proliferative rate in the later, with lower SETD7 levels was already close to the maximum achievable probably 
by the culture conditions as confluence. It remains unresolved whether the increase in cell proliferation in cells 
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treated or not with EGF is caused by SETD7 methylation of YAP protein itself or if SETD7 additional substrates 
are involved. Still, we can associate SETD7 activity to a diminished cell number.  
 
 
Figure 18: Regulation of cell proliferation YAP translocation. YAP translocation can be regulated by EGF downstream 
pathways as MAPK. MAPK is involved in regulation of SETD7 levels and recruitment of AJUBA proteins. These 
processes enhance nuclear translocation to nucleus and increase cell proliferation by cell cycle progression 
 
 
Next, we were interested if the same effect was verified when cells were stimulated to proliferate by activation 
of ERa. This question is relevant because others had shown that SETD7 increases ERa protein levels and 
enhances its transcriptional activity (18,94). Hence, based on our own results with EGF, what would be the 
effect of SETD7 inhibition in cells treated with E2? When we combined SETD7 inhibition and E2 the E2 effect 
was blocked or reduced. That result raised another question: why the combined treatments didn´t generate an 
increase in cell number as did the treatments alone? Our findings reveal that the combined exposure to E2and 
R-PFI caused an arrest on cell cycle thus blocking cell proliferation.   
We also reported that there was an inverse correlation between SETD7 proteins level and ERa proteins level 
when cells were stimulated to proliferate with EGF. So, when cells were stimulated with EGF, SETD7 levels 
diminished and the levels of ERa increased. Our results are not supported by literature because several studies 
reported a reduction on ERa protein and mRNA levels after EGF stimulation(199). But, one study proposes 
that ERα could interact with EGFR after E2 activation and, through MAPK pathway, induce the increase of 
ERa levels. Moreover, several results indicate that there is a requirement of the ERa to drive EGF-
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mediated functions(200,201). Other studies suggest that MAPK-mediated phosphorylation at S118 of the 
receptor protects ERa from degradation via UPS (202). This models could explain the increase on ERa protein 
levels after EGF stimulation. However, we need to carry out additional studies to establish the interplay between 
EGF, ERa and SETD7. 
We explored the effect of SETD7 activity in regulation of ERa protein levels. Our findings show that when 
SETD7 activity is compromised, ERa protein levels increase. A similar behaviour was obtained when cells 
were incubated with proteasome inhibitor PSI. Despite literature reports that SETD7 increases ERa protein 
stability, our results show that when SETD7 activity was inhibited the ERa protein levels are identical to the 
levels obtained when proteasome degradation is inhibited. Consequently, it is possible that SETD7 activity 
negatively regulates ERa turnover. We propose that SETD7 might inhibit E2-induced proliferation through 
increased ERa protein degradation or might negatively regulate ERa gene expression (Figure 19). It was 
reported that N-terminal domain of Rb protein interacts with ERa in breast cancer cells allowing the assembly 
of ERa-Hsp90-p23 protein complex. This complex protects ERa from degradation by the UPS(122). As Rb is 
a SETD7 target, we propose that SETD7 could regulate ERa degradation by inhibition of Rb/ERα interaction 
(Figure 19). But further studies are needed to confirm this hypothesis. 
Finally, we evaluated the impact of SETD7 on ERa activity through measurement of the ERa target gene 
RIP140 protein product. E2 induces RIP140 transcription (203,204). This was verified by us at the protein level. 
RIP140 is an ERa transcriptional co-repressor, so that following E2 activation of ERa,  RIP140 cellular levels 
is high and there is a negative feedback regulation of ERa activity (205,206). For this reason, when cells were 
incubated with R-PFI, the levels of RIP140 were maintained because even though there was more ERa protein 
levels, there was no E2. However, when E2 and R-PFI were used together RIP140 levels increased, suggesting 
that SETD7 inhibition did not affect ERa activity. Thus, considering that the amount of ERa is proportional to 
ERa activity, SETD7 regulates the protein levels of ERa and SETD7 inhibition for 24h does not reduce ERa 
activity. 
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Figure 19: Purposed model of SETD7 regulation in breast cancer cell fate. SETD7 protein levels are upstream 
controlled by growth factors EGF and FGF as well E2. SETD7 could negatively control cell proliferation through inhibition 
of translocation of YAP to nucleus. SETD7 could also be associated to ERa proteasome mediated degradation 
“®” indicate possible interactions in agreement with our results; “-->” indicate a purposed interaction to be posteriorly 
proved. Coact: Coactivator; ERa: Estrogen Receptor a ; E2: 17ß-estradiol; Pol: RNA Polimerase II 
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In summary, in this thesis we successfully established SETD7 as a regulator of breast cancer cell proliferation 
and have gathered some information regarding the role of SETD7 on ERa protein levels and activity. Hence, 
we can consider SETD7 an important protein regulating multiples signaling pathways relevant to breast cancer 
proliferation, including estrogen signaling and RTK-mediated signaling. 
We linked SETD7 to the regulation of cell number and cell proliferation. When cells are stimulated to proliferate 
by E2, EGF or FGF2, SETD7 levels decreased, suggesting that in a high proliferative state, the cell need to 
decrease SETD7 levels. Moreover, SETD7 activity was necessary to restrict cell number, in the absence of E2.  
We show that SETD7 activity regulates ERa protein levels, possibly promoting ERa degradation, but it 
probably dispensable for ERa transcriptional activity in RIP140 target gene, although this hypothesis needs to 
be confirmed by analysing RIP-140 mRNA levels and ERα binding to the RIP-140 promoter SETD7 is indicated 
as inhibitor and promotor of degradation of many substrates. The regulation of ERa can be dependent on many 
factors, other PTMs or even the cell type. Hence, further studies are required to support our findings and to 
verify if the effects here reported can be observed in different breast cancer cell lines. Thus, the next step to 
carry on would be analyse if the levels of ERa-ubiquitinated decrease when SETD7 activity is inhibited with 
the aim of confirm if SETD7 promotes ERa protein degradation. 
SETD7 activity contribute to maintain low levels of ERa protein. In that case, SETD7 also play a role as breast 
cancer tumour suppressor, since overexpression of ERa is frequently observed in early stage of breast cancers 
(207). 
Many of SETD7 targets, including ERa, are involved in carcinogenesis, suggesting that the modulation of 
SETD7 activity could be a new strategy for breast cancer treatment. Our results indicate that specific agonists 
of SETD7 activity could be used for ERa negative breast cancer which is more dependent on EGF signaling. In 
case of ERa-positive breast cancer, SETD7 inhibitors would be preferred.
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8.1. FACS analysis of cell cycle 
 
With the aim to check if the cells could be cell cycle arrested it has been realized a setup experiment using 
FACS analysis. In that experiment T47D were normally grown and cyclate on growth factor-supplemented 
medium (t0). When the cells reached 80% of confluence the medium has been changed by a growth factor-free 
medium (-EGF). In that point, cells were supposed to be arrested on cell cycle (synchronized). Then, 24h later 
the cells synchronized were stimulated with EGF for 12h (EGF 12h) to restart cell cycle.  
By the results obtained, on the figure below it can be observed that at t0 (Figure 20A; A02 T0 box), most of the 
cells are distributed by G0/G1, S and G2/M phase. When the cells were synchronized, it can be observed an 
increase on the cells arrested on G/G1 of the cell cycle and a decrease on the relative frequency of cells in S 
phase, in comparison to t0 (Figure 20A; A03 –EGF box) Finally, once the cells are stimulated with growth 
factors to proliferate again, there is an increase of cells on S phase, in comparison to –EGF condition (Figure 
20A; A04 EGF12hs box) and a reduction of cells in G2/M. That reduction could be explained by the cells that 
had complete cell cycle. In conclusion, 24 hours of growth factor-free medium apparently was sufficient to 
induce an arrest on cell cycle of T47D cells and a stimulation with EGF for 12h was also sufficient to cells 
restart to recycle. The next step of this experiment will be measure by FACS the impact of R-PFI SETD7-
inhibitor, E2 and PSI proteasome inhibitor on each phase of cell cycle to confirm the results previously presented 
by BrdU and immunofluorescence technique. 
 
Figure 20: Cell cycle analysis by FACS assay in T47D cells. A. T47D normally cycling at FBS-supplement medium, 
T47D synchronized by FBS-free medium for 24h and T47D synchronized were incubated with EGF 10ng/mL for 12h 
B. Relative frequency of cell cycle phases on t0, -EGF and EGF12h. 
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